DK2276509T3 - Detektering og behandling af cancer i bugspytkirtel, æggestokke og andre cancere - Google Patents

Detektering og behandling af cancer i bugspytkirtel, æggestokke og andre cancere Download PDF

Info

Publication number
DK2276509T3
DK2276509T3 DK09729923.4T DK09729923T DK2276509T3 DK 2276509 T3 DK2276509 T3 DK 2276509T3 DK 09729923 T DK09729923 T DK 09729923T DK 2276509 T3 DK2276509 T3 DK 2276509T3
Authority
DK
Denmark
Prior art keywords
antibody
cancer
cells
antibodies
expression
Prior art date
Application number
DK09729923.4T
Other languages
English (en)
Inventor
Maria Leia Smith
Maureen Ryan
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of DK2276509T3 publication Critical patent/DK2276509T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (8)

1. Monoklonalt antistof, der specifikt bindes til denatureret human CD70 på en prøve af formalin-fikserede, paraffin-indlejrede celler eller væv, der udtrykker human CD70, og der har variable tungkæderegion-komplementaritetsbestemmende regioner (CDR’er), der har aminosyresekvenser fra CDR’er af den variable tungkæderegion af antistoffet SG-21.1C1 og variable letkæderegion-CDR’er, der har aminosyresekvenserne af CDR’er af den variable letkæderegion af antistoffet SG-21.1C1, som fremstillet af hybridomet, der er indleveret til ATCC og tildelt accessionsnummer PTA-8733, eller variable tungkæderegion CDR’er, der har aminosyresekvenserne af CDR’er af den variable tungkæderegion af antistoffet SG-21.5D12 og variable letkæderegion-CDR’er, der har aminosyresekvenserne af CDR’er af den variable letkæderegion af antistoffet SG-21.5D12, som fremstillet af hybridomet, der er indleveret til ATCC og tildelt accessionsnummer PTA-8734.
2. Antistof ifølge krav 1, der er antistof SG-21.1C1, som er fremstillet af hydridomet, der er indleveret til ATCC og tildelt accessionsnummer PTA- 8733.
3. Antistof ifølge krav 1, der er antistof SG-21.5D12, som er fremstillet af hydridomet, der er indleveret til ATCC og tildelt accessionsnummer PTA- 8734.
4. Antistof ifølge krav 1, der omfatter en variabel tungkæderegion, der er den variable tungkæderegion af antistof SG-21.1C1 og en variabel letkæderegion, der er den variable letkæderegion af antistof SG-21.1C1.
5. Antistof ifølge krav 1, der omfatter en variabel tungkæderegion, der er den variable tungkæderegion af antistof SG-21.5D12 og en variabel letkæderegion, der er den variable letkæderegion af antistof SG-21.5D12.
6. Fremgangsmåde til detektering af ekspression af CD70 i en vævsprøve fra en patient, hvilken fremgangsmåde omfatter opnåelse af en vævsprøve fra patientens bugspytkirtel, æggestokke, lunger, strubehoved, svælg, bryst, nyre, hjerne, kolon, blod eller hud; fiksering af vævsprøven og denaturering af CD70 i vævsprøven; etablering af kontakt mellem den fikserede vævsprøve og antistoffet ifølge et hvilket som helst af kravene 1 til 5; og detektering af binding af antistoffet til den fikserede vævsprøve for bestemmelse af, hvorvidt CD70 er udtrykt i prøven; hvor ekspression af CD70 på den fikserede vævsprøve indikerer en sandsynlighed for, at patienten har en CD70, der udtrykker cancer, hvor prøven er fikseret med formalin og indlejret i paraffin.
7. Fremgangsmåde ifølge krav 6, hvilken fremgangsmåde endvidere omfatter (a) diagnosticering af patienten med en cancer baseret på ekspressionen af CD70 i prøven i forhold til en kontrolvævsprøve; eller (b) prognosticering af tilstedeværelsen af cancer hos patienten baseret på ekspressionen af CD70 i forhold til en kontrolvævsprøve; eller (c) bestemmelse af en behandlingsprotokol til patienten, hvor detekterbar ekspression af CD70 er et tegn på, at behandlingsprotokollen indbefatter behandling med et CD70-antistof eller antistoflægemiddelkonjugat.
8. Fremgangsmåde til diagnosticering, prognosticering, bestemmelse af en behandlingsprotokol eller overvågning af en patient, der har cancer i bugspytkirtel, æggestokke, lunger, strubehoved, svælg, bryst eller hud, glioblastom, multipelt myelom, Flodgkins lymfom, ikke-Flodgkins lymfom, nyrecellekarcinom, kolorektal- eller blærekarcinom, der omfatter bestemmelse af CD70-ekspression i celler i en prøve fra patientens bugspytkirtel, æggestokke, lunge, strubehoved, svælg, bryst, nyre, hjerne, kolon, blod eller hud, ved anvendelse af antistoffet ifølge et hvilket som helst af kravene 1 til 5, hvor tilstedeværelsen af detekterbar CD70-ekspression anvendes i diagnosticeringen, prognosticeringen, bestemmelse af en behandlingsprotokol eller overvågning af behandlingen af patienten, hvor CD70-ekspression er bestemt på cellerne i en formalin-fikseret, paraffin-indlejret prøve.
DK09729923.4T 2008-04-11 2009-04-10 Detektering og behandling af cancer i bugspytkirtel, æggestokke og andre cancere DK2276509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4445708P 2008-04-11 2008-04-11
PCT/US2009/040275 WO2009126934A2 (en) 2008-04-11 2009-04-10 Detection and tratment of pancreatic, ovarian and other cancers

Publications (1)

Publication Number Publication Date
DK2276509T3 true DK2276509T3 (da) 2016-09-19

Family

ID=41162668

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09729923.4T DK2276509T3 (da) 2008-04-11 2009-04-10 Detektering og behandling af cancer i bugspytkirtel, æggestokke og andre cancere

Country Status (16)

Country Link
US (2) US9120854B2 (da)
EP (1) EP2276509B1 (da)
JP (2) JP5752592B2 (da)
KR (1) KR101674097B1 (da)
CN (1) CN102056626B (da)
AU (1) AU2009234267B2 (da)
BR (1) BRPI0906903B8 (da)
CA (1) CA2720699C (da)
DK (1) DK2276509T3 (da)
ES (1) ES2588194T3 (da)
IL (1) IL208517A (da)
MY (1) MY159553A (da)
NZ (1) NZ589063A (da)
RU (1) RU2556129C2 (da)
SG (1) SG189776A1 (da)
WO (1) WO2009126934A2 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58103228A (ja) * 1981-12-16 1983-06-20 Kaga Tsushin Kogyo Kk 光スイツチ方法
GB0522968D0 (en) 2005-11-11 2005-12-21 Popovich Milan M Holographic illumination device
GB0718706D0 (en) 2007-09-25 2007-11-07 Creative Physics Ltd Method and apparatus for reducing laser speckle
US11726332B2 (en) 2009-04-27 2023-08-15 Digilens Inc. Diffractive projection apparatus
US9335604B2 (en) 2013-12-11 2016-05-10 Milan Momcilo Popovich Holographic waveguide display
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
PT2686347T (pt) * 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
CN102719403B (zh) * 2011-03-29 2016-01-20 上海睿智化学研究有限公司 一种人胰腺腺鳞癌细胞系及其建立方法和应用
US9274349B2 (en) 2011-04-07 2016-03-01 Digilens Inc. Laser despeckler based on angular diversity
US10670876B2 (en) 2011-08-24 2020-06-02 Digilens Inc. Waveguide laser illuminator incorporating a despeckler
WO2016020630A2 (en) 2014-08-08 2016-02-11 Milan Momcilo Popovich Waveguide laser illuminator incorporating a despeckler
EP2748670B1 (en) 2011-08-24 2015-11-18 Rockwell Collins, Inc. Wearable data display
KR102007055B1 (ko) 2011-09-22 2019-08-02 암젠 인크 Cd27l 항원 결합 단백질
US20150010265A1 (en) 2012-01-06 2015-01-08 Milan, Momcilo POPOVICH Contact image sensor using switchable bragg gratings
US10940167B2 (en) * 2012-02-10 2021-03-09 Cvdevices, Llc Methods and uses of biological tissues for various stent and other medical applications
CN103562802B (zh) 2012-04-25 2016-08-17 罗克韦尔柯林斯公司 全息广角显示器
WO2013167864A1 (en) 2012-05-11 2013-11-14 Milan Momcilo Popovich Apparatus for eye tracking
US9933684B2 (en) 2012-11-16 2018-04-03 Rockwell Collins, Inc. Transparent waveguide display providing upper and lower fields of view having a specific light output aperture configuration
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014158821A1 (en) * 2013-03-12 2014-10-02 Imaginab, Inc. Antigen binding constructs to cd70
US10570151B2 (en) * 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
WO2014188149A1 (en) 2013-05-20 2014-11-27 Milan Momcilo Popovich Holographic waveguide eye tracker
WO2015015138A1 (en) 2013-07-31 2015-02-05 Milan Momcilo Popovich Method and apparatus for contact image sensing
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
MA47811A (fr) 2014-04-25 2019-06-19 Pf Medicament Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
WO2015183978A1 (en) * 2014-05-28 2015-12-03 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
DE102014108642B3 (de) * 2014-06-19 2015-12-03 Laser Zentrum Hannover E.V. Einbettmedium für biologische Proben und Verfahren zum Herstellen von eingebetteten biologischen Proben sowie deren Verwendung
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
WO2016020632A1 (en) 2014-08-08 2016-02-11 Milan Momcilo Popovich Method for holographic mastering and replication
US10241330B2 (en) 2014-09-19 2019-03-26 Digilens, Inc. Method and apparatus for generating input images for holographic waveguide displays
WO2016046514A1 (en) 2014-09-26 2016-03-31 LOKOVIC, Kimberly, Sun Holographic waveguide opticaltracker
EP3245444B1 (en) 2015-01-12 2021-09-08 DigiLens Inc. Environmentally isolated waveguide display
WO2016113533A2 (en) 2015-01-12 2016-07-21 Milan Momcilo Popovich Holographic waveguide light field displays
WO2016116733A1 (en) 2015-01-20 2016-07-28 Milan Momcilo Popovich Holographic waveguide lidar
US9632226B2 (en) 2015-02-12 2017-04-25 Digilens Inc. Waveguide grating device
US10459145B2 (en) 2015-03-16 2019-10-29 Digilens Inc. Waveguide device incorporating a light pipe
WO2016156776A1 (en) 2015-03-31 2016-10-06 Milan Momcilo Popovich Method and apparatus for contact image sensing
EP3359999A1 (en) 2015-10-05 2018-08-15 Popovich, Milan Momcilo Waveguide display
WO2017134412A1 (en) 2016-02-04 2017-08-10 Milan Momcilo Popovich Holographic waveguide optical tracker
EP3433659A1 (en) 2016-03-24 2019-01-30 DigiLens, Inc. Method and apparatus for providing a polarization selective holographic waveguide device
EP3433658B1 (en) 2016-04-11 2023-08-09 DigiLens, Inc. Holographic waveguide apparatus for structured light projection
EP3548939A4 (en) 2016-12-02 2020-11-25 DigiLens Inc. UNIFORM OUTPUT LIGHTING WAVEGUIDE DEVICE
US10545346B2 (en) 2017-01-05 2020-01-28 Digilens Inc. Wearable heads up displays
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3621981A2 (en) 2017-05-12 2020-03-18 CRISPR Therapeutics AG Materials and methods for engineering cells and uses thereof in immuno-oncology
US10942430B2 (en) 2017-10-16 2021-03-09 Digilens Inc. Systems and methods for multiplying the image resolution of a pixelated display
CN115356905A (zh) 2018-01-08 2022-11-18 迪吉伦斯公司 波导单元格中全息光栅高吞吐量记录的系统和方法
WO2019136476A1 (en) 2018-01-08 2019-07-11 Digilens, Inc. Waveguide architectures and related methods of manufacturing
EP3694546A1 (en) 2018-01-30 2020-08-19 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
EP3765897B1 (en) 2018-03-16 2024-01-17 Digilens Inc. Holographic waveguides incorporating birefringence control and methods for their fabrication
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US11402801B2 (en) 2018-07-25 2022-08-02 Digilens Inc. Systems and methods for fabricating a multilayer optical structure
KR20210138609A (ko) 2019-02-15 2021-11-19 디지렌즈 인코포레이티드. 일체형 격자를 이용하여 홀로그래픽 도파관 디스플레이를 제공하기 위한 방법 및 장치
KR20210134763A (ko) 2019-03-12 2021-11-10 디지렌즈 인코포레이티드. 홀로그래픽 도파관 백라이트 및 관련된 제조 방법
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CN114207492A (zh) 2019-06-07 2022-03-18 迪吉伦斯公司 带透射光栅和反射光栅的波导及其生产方法
KR20220038452A (ko) 2019-07-29 2022-03-28 디지렌즈 인코포레이티드. 픽셀화된 디스플레이의 이미지 해상도와 시야를 증배하는 방법 및 장치
KR20220054386A (ko) 2019-08-29 2022-05-02 디지렌즈 인코포레이티드. 진공 브래그 격자 및 이의 제조 방법
WO2021245603A1 (en) * 2020-06-04 2021-12-09 Crispr Therapeutics Ag Anti-cd70 antibodies and uses thereof
RU2750472C1 (ru) * 2021-01-26 2021-06-28 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Малоинвазивный способ диагностики серозной аденокарциномы яичников высокой степени злокачественности на основании показателя копийности генов SULT1E1, CYP1B1 и ESR1
CN113754769B (zh) * 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1999036565A1 (en) * 1998-01-14 1999-07-22 Human Genome Sciences, Inc. Human ependymin
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
ES2394018T3 (es) 2001-11-27 2013-01-15 Ucb Pharma S.A. Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7615211B2 (en) 2004-02-09 2009-11-10 Cbr Institute For Biomedical Research, Inc. CD70 inhibition for the treatment and prevention of inflammatory bowel disease
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP3363907A1 (en) * 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
ES2527961T3 (es) * 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.

Also Published As

Publication number Publication date
RU2010145942A (ru) 2012-05-20
IL208517A0 (en) 2010-12-30
JP2014218502A (ja) 2014-11-20
RU2556129C2 (ru) 2015-07-10
US20160003847A1 (en) 2016-01-07
WO2009126934A2 (en) 2009-10-15
CN102056626B (zh) 2016-07-06
EP2276509A2 (en) 2011-01-26
KR101674097B1 (ko) 2016-11-08
EP2276509A4 (en) 2013-03-13
EP2276509B1 (en) 2016-06-15
AU2009234267A1 (en) 2009-10-15
AU2009234267B2 (en) 2014-10-30
IL208517A (en) 2016-06-30
MY159553A (en) 2017-01-13
CA2720699C (en) 2018-01-02
WO2009126934A3 (en) 2009-12-30
SG189776A1 (en) 2013-05-31
BRPI0906903B8 (pt) 2021-05-25
CN102056626A (zh) 2011-05-11
NZ589063A (en) 2012-10-26
JP5752592B2 (ja) 2015-07-22
BRPI0906903B1 (pt) 2020-07-07
US9120854B2 (en) 2015-09-01
BRPI0906903A2 (pt) 2015-12-01
KR20110010719A (ko) 2011-02-07
CA2720699A1 (en) 2009-10-15
JP2011520782A (ja) 2011-07-21
US20110300131A1 (en) 2011-12-08
ES2588194T3 (es) 2016-10-31

Similar Documents

Publication Publication Date Title
DK2276509T3 (da) Detektering og behandling af cancer i bugspytkirtel, æggestokke og andre cancere
US20230099149A1 (en) Treatment of cancer
CN111212853A (zh) 可活化的抗cd166抗体及其使用方法
CN113260383A (zh) 可活化的抗cd166抗体及其使用方法
KR102520974B1 (ko) 요로상피 암종의 치료에서 항―ｈｅｒ２ 항체―약물 접합체의 용도
AU2015200386A1 (en) Detection and treatment of pancreatic, ovarian and other cancers
US20220373553A1 (en) Detection and treatment of cd30+ cancers
JP6122948B2 (ja) 胃癌の治療のための方法
US20220411532A1 (en) Antibodies targeting an amphiregulin-derived cell surface neo-epitope